ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,384,852, issued on Aug. 12, was assigned to Institute for Cancer Research (Philadelphia) and ImmunityBio Inc. (San Diego).
"Genetically modified NK-92 cells having a safety switch" was invented by Tien Lee (San Diego), Hans G. Klingemann (San Diego), Barry J. Simon (San Diego), Laurent Boissel (San Diego) and Kerry Campbell (Wyncote, Pa.).
According to the abstract* released by the U.S. Patent & Trademark Office: "This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor."
The patent was filed on Nov. 18, 2021, under Application No. 17/530,211.
*For furth...